In the United States,<unk>  is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for adults and children one month and older and for the treatment of relapsed or refractory CD33-positive AML in adults and children two years and older.
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Ranibizumab
Ponatinib
Bevacizumab
Ruxolitinib
Dasatinib
Imatinib